BC PharmaCare lists Maviret™ treatment for HCV

Congratulations, hepatitis C patients in BC, BC PharmaCare, and AbbVie Pharmaceuticals! One more treatment option is now available to BC HCV patients of all genotypes, New patients without cirrhosis need only 8 weeks treatment. Maviret™ is also safe and effective for the many HCV+ people with chronic kidney disease (CKD). More information: https://www.newswire.ca/news-releases/british-columbia-pharmacare-lists-abbvie-s-hepatitis-c-treatment-mavi...

URGENT REQUEST for patient input into INTERFERON-FREE HCV 3-drug combo by AbbVie

We've been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE 3-drug combo ombitasvir (ABT-267), paritaprevir (ABT-450)+ritonavir, and dasubuvir (ABT-333) which was developed for Chronic Hepatitis C by pharmaceutical company, AbbVie. We urgently request input from individual HCV+ people with any genotype (both those who have and have not tried this drug combination). For background info see http://hepcbc.ca/contribute-to-abbvie-3d-su

PDF of WEBINAR about SOFOSBUVIR and LEDIPASVIR COMBO – Dr. Paul Marotta, Sept. 8, 2014

On Sept. 8, 2014, Dr. Paul Marotta of London Health Sciences Centre, presented "Transformation of HCV Management: The IFN-free Era". To access a PDF of this highly-informative and "up-to-the-minute" presentation, click HERE: DrPaulMarotta_20140908_HCV_Treatment_Presentation. Many thanks, Dr. Marotta, for generously sharing these excellent materials with HepCBC's online members.

Fighting to make HCV treatment affordable for 170 million people

Bangkok, Thailand, Feb. 28, 2014 (press release): "Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection t

Speech to CATIE 2013 Focuses on Unmet Needs of HCV+ Population

An HCV+ member of HepCBC was asked to give a 10-minute speech at CATIE (Canadian AIDS Treatment Information Exchange) last week about what sort of policies HCV+ people hoped would come about in the next 5 years. Lots of illustrations/images. Here is the speech: VIDEO: http://www.catie.ca/en/forum/webcast-archive/closing-plenary#reitz PDF: http://www.hcvadvocate.org/community/community_pdf/HepCBC_CATIE_2013.pdf